Tag: US cancer immunotherapy market

Save up to 30% on The Business Research Company’s comprehensive market research reports for a limited time only!

What is the Expected Growth Rate of the Cancer Immunotherapy Market from 2024 to 2033?

The cancer immunotherapy market is projected to rise from $97.88 billion in 2023 to $110.91 billion in 2024, reflecting a CAGR of 13.3%. This growth is driven by the rising prevalence of cancer, the growing adoption of immunotherapy over traditional therapies, increased research and development in targeted treatments, enhanced efficacy and precision of newer therapies, and recognition of the limitations of conventional cancer treatments.

The cancer immunotherapy market is expected to grow rapidly, reaching $175.39 billion by 2028 at a CAGR of 12.1%. Growth drivers include increasing approval of novel immunotherapies, rising demand for personalized medicine, growing cancer cases, increased investment in clinical trials, and growing awareness of immunotherapy. Major trends include the emergence of adoptive cell therapies, exploration of oncolytic viruses, personalized cancer vaccines, AI in immunotherapy research, and the growing focus on real-world evidence.

Claim Your Free Sample of the Global Cancer Immunotherapy Market Report Today!

https://www.thebusinessresearchcompany.com/sample.aspx?id=6768&type=smp

What Key Factors Are Fueling the Growth of the cancer immunotherapy Market?

The rise in cancer incidence is expected to propel the cancer immunotherapy market. Factors such as tobacco use, alcohol consumption, obesity, sedentary lifestyles, and environmental factors contribute to the increase in cancer cases globally. The rising incidence of cancer is expected to drive the demand for cancer immunotherapies as patients seek effective and less painful medical treatments. The data from the European Union Science Hub underscores the growth in new cancer cases, supporting the anticipated boost in the cancer immunotherapy market.

What Are the Major Segments of the Cancer Immunotherapy Market?

1) By Product: Monoclonal Antibodies, Checkpoint Inhibitors, Immunomodulators, Vaccines, Cell Therapy

2) By Application: Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Multiple Myeloma

3) By End User: Hospitals, Cancer Research Centers, Clinics

What New Trends Are Transforming the 126 Market?

Advanced technologies used in cancer immunotherapy are driving innovation in the cancer immunotherapy market, offering new therapies to help the immune system fight tumors. For example, in October 2022, AstraZeneca plc received approval for its Capivasertib in combination with Faslodex for the treatment of breast cancer. This drug, a cancer immunotherapeutic, is effective in treating locally progressed or metastatic breast cancer with low or negative human epidermal growth factor receptor 2 (HER2) following recurrence or progression after endocrine therapy.

Order Now for Fast Delivery of Your Cancer Immunotherapy Market Report!

https://www.thebusinessresearchcompany.com/report/cancer-immunotherapy-global-market-report

Which Regions Are Driving Growth in the Cancer Immunotherapy Market?

North America was the largest region in the cancer immunotherapy market in 2023 and is also expected to be the fastest-growing region in the forecast period. The regions covered in the cancer immunotherapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The Cancer Immunotherapy Global Market Report 2024 offers a comprehensive overview of the audio equipment market, covering historical data from 2010 to 2021 and providing a ten-year forecast from 2023 to 2032. This report examines the size of the cancer immunotherapy market, its market share, and analyzes key competitors along with their market positions.

The Table Of Content For The Cancer Immunotherapy Market Include

1. Cancer Immunotherapy Market Executive Summary

2. Cancer Immunotherapy Market Segments

3. Cancer Immunotherapy Market Size And Template Market Growth Rate

4. Key Cancer Immunotherapy Market Trends

5. Major Cancer Immunotherapy Market Drivers

……

25. Key Mergers And Acquisitions In The Cancer Immunotherapy Market

26. Top Cancer Immunotherapy Companies

27. Cancer Immunotherapy Market Opportunities And Strategies

28. Cancer Immunotherapy Market, Conclusions And Recommendations

29. Appendix

Learn More About The Business Research Company

The Business Research Company has published over 15000+ reports in 27 industries, spanning 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

 

The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2024 and forecasted to 2033

The cancer immunotherapy market has witnessed rapid growth, poised to surge from $97.88 billion in 2023 to $110.91 billion in 2024, representing a robust Compound Annual Growth Rate (CAGR) of 13.3%. Looking ahead, the forecast predicts a continued upward trajectory, reaching $175.39 billion in 2028 with a CAGR of 12.1%. Several factors contribute to this growth, underpinned by a shift towards immunotherapy over traditional methods, increased research and development activities, and a deeper understanding of the limitations of conventional cancer treatments.

Driving Forces: Cancer Incidence Surge and the Surge in Cancer Immunotherapy Demand

Global Rise in Cancer Cases

The surge in cancer incidence is a pivotal driver propelling the demand for cancer immunotherapy. Lifestyle factors like tobacco and alcohol consumption, obesity, sedentary living, and environmental influences contribute to the escalating number of cancer cases worldwide. Recent data from the European Union Science Hub indicates a 2.3% increase in new cancer cases over two years, reaching 2.74 million in 2022, emphasizing the urgency for effective treatments.

Industry Giants at the Helm

Major players in the cancer immunotherapy market, including Amgen Inc., AstraZeneca PLC, and Roche Ltd., are actively contributing to the advancements in immunotherapy. These companies play a crucial role in meeting the growing demand for innovative treatments, focusing on enhancing recovery outcomes with minimal patient discomfort.

Revolutionizing Cancer Treatment: Imjudo and Imfinzi Combination

Innovative Approaches to Therapy

Leading companies in the cancer immunotherapy market are spearheading innovations to address consumer needs. AstraZeneca’s Imjudo, a blend of Imfinzi and tremelimumab, serves as a dual immune checkpoint inhibitor. Notably, this combination gained approval in October 2022 for treating unresectable hepatocellular carcinoma (HCC). The STRIDE regimen, with a unique dosing schedule, showcases the industry’s commitment to refining treatment modalities.

View More On The Cancer Immunotherapy Market Report 2024 – https://www.thebusinessresearchcompany.com/report/cancer-immunotherapy-global-market-report

Strategic Acquisitions: Bayer’s Endeavor with Vividion Therapeutics

Bolstering Research Expertise

In a strategic move in August 2021, Bayer AG acquired Vividion Therapeutics for $1.5 billion. This acquisition enhances Bayer’s capabilities in drug discovery and research, introducing new chemoproteomic screening technology and a chemistry library. Vividion’s expertise offers precision in treating cancers and immunological disorders, targeting previously inaccessible high-value areas.

Segmentation Insights: Navigating the Diverse Landscape

Understanding Market Dynamics

The cancer immunotherapy market is categorized based on products, applications, and end-users, reflecting the diverse landscape of this dynamic sector. Segments include Monoclonal Antibodies, Checkpoint Inhibitors, Immunomodulators, Vaccines, and Cell Therapy, catering to diverse cancer types such as Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, and Multiple Myeloma. End-users span Hospitals, Cancer Research Centers, and Clinics.

Regional Dynamics: North America Takes the Lead

Dominance and Growth

In 2023, North America emerged as the largest region in the cancer immunotherapy market, a trend expected to persist into the forecast period. The region not only boasts significant market share but is also projected to experience the fastest growth. This can be attributed to factors such as robust healthcare infrastructure, technological advancements, and a proactive approach to cancer research and treatment.

Conclusion: Paving the Way Forward

Embracing Advancements

As the cancer immunotherapy market expands, driven by a surge in cancer incidence and heightened demand for effective treatments, the industry is witnessing unprecedented advancements. Companies are at the forefront of innovation, developing novel therapies and leveraging strategic acquisitions to enhance research capabilities. With a focus on personalized medicine, the future promises groundbreaking approaches to cancer treatment, offering hope to millions around the globe. The trajectory ahead is one of continual growth and evolution in the pursuit of conquering cancer through immunotherapy.

Request A Sample Of The Global Cancer Immunotherapy Market Report 2024:
https://www.thebusinessresearchcompany.com/sample_request?id=6768&type=smp